Minerva Neurosciences | NERV - Ordinary Share Capital


Minerva Neurosciences reported $1000 in Ordinary Share Capital for its fiscal quarter ending in September of 2024.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Adma Biologics USD 232.29M 5.59M Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
AstraZeneca USD 1.55B 44K Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cipla INR 807.78M 17K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1000 Mar/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Grifols EUR 680.58M 846.11K Dec/2025
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Takeda JPY 1.58B 460K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024